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The use of hormone therapy (HT) after menopause re-
mains the object of controversy, as the first observational 
investigations had revealed significant reduction in mor-
tality among therapy users compared with nonusers1.
However, after the publication of Women’s Health Ini-
tiative (WHI)2, it was observed exactly the opposite, i.e., 
HT was associated with a higher rate of morbimortality 
regardless of age, which culminated with the recommen-
dation that it should be prescribed only for short periods 
and only for menopausal symptoms3,4.
Since then, many women have abruptly discontinued 
HT, resulting in a significant deterioration in quality of life5.
Therefore, in an attempt to clarify the question of the 
effect of HT at different ages two meta-analyses were pub-
lished involving randomized trials, of which results sur-
prisingly found a reduction in cardiovascular events and 
mortality in younger women, but not in older women5.
In 2009, Salpeter et al.6 published an interesting ar-
ticle in The American Journal of Medicine dealing with 
the controversial issue of HT after menopause where they 
analyzed their impact on the cost and quality of life in two 
groups of women after menopause. For that purpose, a 
mathematical model evaluating the cost-effectiveness in 
different age groups was used. The results showed signifi-
cant advances in the window of opportunity hypothesis 
for the use of HT because the study compared two groups 
of women, a younger post-menopausal (up to 59  years) 
and an older one (>  60  years). The mathematical model 
was based on the meta-analysis of randomized controlled 
clinical trials conducted until March 2008, and assessed 
the QALY (quality-adjusted-life years) that represents the 
cost-benefit of HT on the quality of life of women after 
menopause.
In conclusion, the study reported favorable cost-ben-
efit of HT in the younger group, which did not occur in 
the older group; in fact, the young group had a gain of 
1.49 QALYs, at a cost of US$ 2,438 (value < US$10,000 are 
considered to be significantly cost-effective). On the other 
hand, in the older group, the QALY gain was only 0.11, at 
a cost of US$ 27,953. Moreover, in the first nine years of 
treatment a worsening in quality of life of older women was 
observed, and only after this period an improvement 
was observed. In the young group, improvement in QALY 
was theoretically demonstrated with a treatment period 
that lasted up to 30 years.
These same authors have demonstrated in a meta-anal-
ysis of controlled clinical trials the occurrence of mortality 
decrease in younger women who used HT, with no benefit 
to the group who started HT later.
Thus, the results obtained in this study are consistent 
with those reported previously in observational designs – 
which had included younger women who started HT soon 
after menopause, that is, who showed improvement in 
quality of life and reduction in cardiac events. Moreover, 
it corroborates the results obtained from controlled clini-
cal trials that assessed older women, such as the Women’s 
Health Initiative, which showed no reduction in mortality.
Based on these studies, the Brazilian and International 
Guidelines have recommended to date the use of HT in 
women with menopausal symptoms, such as hot flashes, 
insomnia, vaginal dryness, from the stage of menopausal 
transition and discouraged its start many years after the 
age of menopause.
However, two recent studies regarding the risk of breast 
cancer have disclosed surprising results.
The first study, published in February 2011 by 
Beral et al.7 of the Million Women Study (MWS) analyzed 
the relative risk (RR) of breast cancer in users and nonusers 
of HT in a United Kingdom population of 1,129,025 post-
menopausal women by adjusted Cox’s regression, based 
on prospective information. The authors observed that 
the relative risk of breast cancer in HT users was greater 
when initiated before or soon after menopause, than af-
ter a long period of time (p heterogeneity < 0.001 for both 
groups of HT users: estrogen with progestin and estrogen 
only). Among users of estrogen formulations only, the in-
creased risk was slight or none when the steroid had been 
used for five or more years after menopause (RR = 1.05, 
95% CI = 0.89 to 1.24), although when the use of estrogen 
alone was initiated before or within less than five years of 
menopause, the risk was significantly higher (RR = 1.43, 
95% CI = 1.35 to 1.51).
A similar pattern was observed among users of com-
bined estrogen with progestin (RR = 1.53, 95% CI = 1.38 
to 1.70 and RR = 2.04, 95% CI = 1.95 to 2.14, respectively).
In patients 50-59 years of age, the yearly incidence rates 
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for breast cancer were 0.30% (95% CI = 0.29% to 0.31%) 
in non-users of HT and 0.43% (95% CI = 0.42% to 0.45%) 
and 0.61% (95% CI = 0.59% to 0.64%%), respectively, in 
users of estrogen alone and estrogen combined with pro-
gestin that had started HT before five years after meno-
pause. From these results, the authors concluded that risk 
of breast cancer among HT users was higher in those using 
the combined estrogen-progestin therapy than in those 
who used estrogen-only formulations and that the start 
of the HT was associated before than in those who used 
estrogen-only formulations and that the start of the HT 
before or soon after the menopause onset was associated 
with a higher risk than if it had been started five years after 
menopause. These data indicate that the moment of HT 
start in relation to the menopause onset seems to be an 
important risk modulator associated with breast cancer. 
An interesting fact that was commented in the edito-
rial accompanying the study, which refers to the fact that 
the risk of breast cancer in both groups of HT users has 
been attenuated by overweight and obesity, a result that 
had already been observed in other studies. However, 
when the incidence rates, rather than the relative risk were 
calculated, it became clear that this attenuation is apparent 
and was driven by higher incidence of breast cancer in HT 
non-users with adiposity. In fact, among the non-users but 
not among users of hormone therapy, incidence of breast 
cancer was higher with increasing adiposity. Thus, the pro-
portional increase in breast cancer risk among hormone 
users was lower in those who were overweight and obese 
than among women within normal weight range. Eleva-
tion in blood concentrations of endogenous estrogens, by 
increasing the body mass index among HT non-users, ex-
plains, albeit not completely, the higher risk of breast can-
cer after menopause with increasing adiposity. As blood 
concentrations of endogenous estrogen usually increase 
with adiposity in women after menopause, it seems plau-
sible that hormone therapy could alter the exposure to sex 
hormones to a greater extent in normal weighed women 
than in obese ones. In fact, among obese women users of 
estrogen only, the incidence rates of breast cancer did not 
differ statistically from non-users. 
Epidemiological evidence consistently show that the 
risk of breast cancer among HT users returns to that of 
non-users, as soon as they cease their use. The observed 
decline in incidence rates of breast cancer in the United 
States and in many other countries after 2002, following 
the reduction in the prevalence of HT use provides inde-
pendent support for the epidemiological data.
Obesity and the interval between the menopause on-
set and HT start appear to be important factors, so in the 
WHI2, 80% of the participants were overweight or obese 
and approximately 90% were randomized to hormone 
therapy lasting five or more years after menopause. Among 
the estrogen users, the Million Women Study found little 
or no increased risk of breast cancer in overweight or obese 
women who started hormone therapy five or more years af-
ter menopause (RR = 0.91, 95% CI = 0.73 to 1.14), consistent 
with the results of WHI (RR = 0.77, 95% CI = 0.59 to 1.01). 
The values  for users of estrogen-progestin (RR  =  1.39, 
95% CI = 1.18 to 1.64) were also consistent with the results 
of WHI (RR = 1.26, 95% CI = 1, 00 to 1.59).
Moreover, in the MWS incidence rates of breast can-
cer associated with estrogen plus progestin in users start-
ing five or more years after menopause were similar to 
those observed in WHI (0.46% a year vs. 0.43% a year) 
and 0.3% a year in non-users of HT, both in MWS and 
WHI. However, incidence rates of breast cancer in MWS 
were higher among users of estrogen-progestin that 
started the association before five years after menopause 
(0.61% a year). This result was not a random one, as the 
vast majority of women had been randomly assigned to 
using estrogen after five years of menopause. Thus, the 
results of randomized trials of hormone therapy in rela-
tion to breast cancer risk such as the WHI may not apply 
to women who started hormone therapy close to the time 
of menopause onset.
The second study, published in 2011 by Lacroix et al.8 
of the WHI, evaluated after 10.7 years users of conjugated 
equine estrogen (CEE) submitted to hysterectomy, regard-
ing the risk of coronary heart disease, invasive breast can-
cer, stroke, deep vein thrombosis (DVT), colorectal cancer, 
hip fractures and death. It should be recalled that this 
arm of WHI in hysterectomized women was suspended 
after 7.1 years of follow-up due to higher stroke risk, in 
spite of its low probability to alter the risk benefit of HT 
use. The results of this arm, after intervention, had not 
yet been published and refer to a population of 10,739 
hysterectomized women 50 to 79 years and users of a 
dose of 0.625 mg CEE/day. The follow-up of this study 
continued until August 2009, with 7,645 surviving par-
ticipants (78%).
The results obtained, regarding the annual risk after 
the intervention, among CEE users compared with the 
placebo group were respectively: for coronary artery dis-
ease [0.64% vs. 0.67% (HR 0.97, 95% CI, 0.75-1.25)]; breast 
cancer [0.26% vs. 0.34% (HR 0.75, 95% CI, 0.51 - 1:09)] 
and stroke [0.36% vs. 0.41% (HR 0.89, 95% CI, 0.64-1.24)], 
with the risk of DVT still not high after the intervention 
[0.17% vs. 0.27% (HR 0.63, 95% CI, 0.410.98)], the risk of 
hip fracture after the intervention was lower [0.36% vs. 
0.28% (HR, 1.27, 95% CI, 0.88-1.82)] and the risk of total 
mortality did not show any difference [1.47% vs. 1.48% 
(HR, 1.00, 95% CI, 0.84-1.18)]. 
It is noteworthy the fact that, throughout the follow-
up period, the incidence of breast cancer was persistently 
lower in the CEE group when compared with placebo, 
i.e., it was respectively 0.27% vs. 0.35% (HR 0.77, 95% 
CI, 0.62-0.95). Additionally, all other observed results 
SO, NOW WHAT? WHAT ARE THE RISKS OF BREAST CANCER AND MYOCARDIAL INFARCTION AMONG WOMEN RECEIVING HORMONAL REPLACEMENT THERAPY AFTER MENOPAUSE?
357Rev Assoc Med Bras 2011; 57(4):355-357
were more favorable in younger women (50 to 59 years) 
than in older ones (70 to 79 years) such as in coronary 
artery disease (p = 0.05 for the interaction), myocardial 
infarction (p  =  0.007 for interaction), colorectal cancer 
(p  =  0.04 for interaction), total mortality (p  =  0.04 for 
interaction) and the overall index for chronic diseases 
(p = 0.009 for interaction). Thus, the authors concluded 
in a general analysis of the results that the use of CEE 
by hysterectomized women after menopause followed by 
10.7 years and having used CEE for a mean of 5.9 years 
did not result in an increase or decrease in the risk of cor-
onary artery disease, DVT, stroke, hip fracture, colorectal 
cancer or total mortality, whereas the breast cancer risk 
remained decreased. 
However, in an analysis by age range the authors ob-
served that in regard to the risk of myocardial infarc-
tion, colon cancer and all causes of mortality among 
younger CEE users (50 to 59 years at baseline) showed 
much more favorable results than in the older ones (70 
to 79 years).
Undeniably, the most significant result refers to the 
outcomes of coronary heart disease, where the risk of 
myocardial infarction decreased by 40% to 50% in CEE 
users than in the placebo group of the same age, but 
was higher in women aged 70 to 79 years. Thus, in ab-
solute numbers, for each 10,000 users-year of CEE aged 
between 50 and 59 years there was a reduction of 12 
cases of heart attacks, 13 deaths and 18 adverse events, 
differently from women between 70 and 79 years, where 
for every 10,000 CEE users there was an increase of 16 
heart attacks, 19 deaths and 48 adverse events (p-values 
for interaction with age were statistically significant).
These results add further support to the so-called 
“window of opportunity” (timing hypothesis) regarding 
the prescription of HT. However, it is unclear whether 
these results concerning the reduction in the risk of in-
vasive breast cancer can be applied to all menopausal 
women, as well as to users of estradiol or other estrogen 
formulations, and whether this reduction persists after 
a longer usage.
It appears that these two studies may have a big im-
pact and possibly change the opinion of the American 
Heart Association, the United States Preventive Services 
Task Force, and the Brazilian Society of Cardiology. The 
latter together with the Brazilian Society of Climacte-
rium have issued recommendations advising against the 
use of HT with the isolated objective of preventing car-
diovascular events, because until then, the indication 
for HT was restricted to menopausal symptom control 
in relatively young women (or a few years after meno-
pause). Also still recommended is the restricted use to 
a few years, a fact that had also been confirmed by a 
Cochrane systematic review of 19 clinical trials involv-
ing 41,904 women.
Therefore, the study of LaCroix8 confirmed recent 
evidence from controlled clinical trials that had already 
shown HT benefits in younger women (between 50 and 
59 years), such as a reduction in cardiac events and cor-
onary calcification. The study also stresses the need for 
more controlled investigations, such as the Kronos Early 
Estrogen Prevention Study (KEEPS) started in 2005 and 
scheduled to end this year and which main objective was 
precisely to evaluate in healthy younger women (between 
42 and 58 years), the impact of HT on the carotid intima-
media thickness and coronary calcium content.
FINAL CONSIDERATIONS 
Currently with the available scientific knowledge, HT is 
indicated for the treatment of hot flashes and genital at-
rophy attenuation, but not for primary or secondary pre-
vention of cardiovascular disease. However, regarding the 
recent menopause period, there is evidence that HT could 
reduce the progression of atherosclerosis and the inci-
dence of myocardial infarction, but not of stroke; the WHI 
finished study clearly demonstrates that conjugated equine 
estrogen users aged between 50 and 59 years showed sig-
nificant reduction in risk of myocardial infarction, without 
increasing the risk of stroke and breast cancer.
These findings, although relevant, must be critically 
considered in the overall healthcare of women during 
menopause, taking into account the fact that HT repre-
sents only one of the interventions and, when indicated, 
should always be combined with changes in lifestyle, such 
as regular exercises, balanced diet and elimination of 
smoking, among others.
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